Swiss Bourse Turns to Smaller UK Exchange for Trade Tech Revamp
SIX Group AG, the operator of the Swiss and Spanish bourses, is weighing a switch to the trading technology of Aquis Exchange Plc, a smaller UK exchange it is in the process of acquiring.
The group has been studying whether Aquis's matching engine — the software component that pairs orders and processes transactions — can support trading in Swiss and Spanish stocks before the acquisition is expected to close this quarter, SIX Chief Executive Officer Bjørn Sibbern, said in an interview.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Real Madrid 1st, Barcelona climbing: Updated list of Europe's most valuable clubs
A fresh insight into the most valubale clubs in Europe has this week been forthcoming, following the close of the 2024/25 campaign. And a pair of Spanish sides feature prominently towards the top of the list. Advertisement The info is provided by consulting firm Football Benchmark (as cited by Mundo Deportivo), who have calculated the 'Enterprise Value' of the continent's leading 32 clubs. Topping the pile once more at present are Real Madrid, whose current worth is estimated at a whopping €6.278 billion. Los Blancos are followed by a pair of Premier League clubs in Manchester City and Manchester United respectively in 2nd and 3rd. Barcelona, meanwhile, have jumped a pair of places after rattling off a domestic treble this past season, leapfrogging both Bayern Munich and Liverpool into 4th spot. This comes owing to 'a 26% reduction in personnel costs compared to the previous season', enough to push the Blaugrana's value to €4.459 billion. Conor Laird – GSFN
Yahoo
2 hours ago
- Yahoo
Real Madrid will consider signing fourth defender this summer
Real Madrid intend to head to the Club World Cup with an almost entirely new backline this summer, but they may not be finished yet with the strengthening of their defence. Following the signings of right-back Trent Alexander-Arnold and central defender Dean Huijsen, Los Blancos are expected to bring in a left-back. That presumably would cast doubt over the futures of Ferland Mendy and Fran Garcia. Real Madrid have been in talks with Benfica for Spanish left-back Alvaro Carreras, with personal terms already agreed. Benfica are digging their heels in over his €50m release clause, which Los Blancos are keen to bring down. They have a week to resolve the issue, with the pre-Club World Cup transfer window ending next Tuesday. Real Madrid will assess backline after Club World Cup New manager Xabi Alonso is set to use a 4-3-3 formation initially in the United States, and will work towards using that formation. Currently he and his staff do not believe they have the pieces to play in a back three, and as such will move forward with two central defenders. Eder Militao, Antonio Rudiger and David Alaba are all coming back from injuries, while Raul Asencio and Dean Huijsen come into the tournament in the best form. Image via Europa Press There remains doubt about their defensive options though, and Marca say that they will be under examination during the Club World Cup. Real Madrid will consider signing a second central defender this summer if they are not convinced by what they see. Academy duo to be given a chance While the starlet of La Fabrica before his cruciate ligament injury last summer was 17-year-old Joan Martinez, Alonso will assess two of their other emerging talents at the Club World Cup. Jacobo Ramon began playing under Carlo Ancelotti in situations of need, and was highly praised by the Italian. Meanwhile Diego Aguado, who can also play left-back is to be called up for the trip to the USA too.
Yahoo
2 hours ago
- Yahoo
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a drug technology that the drugmaker has pioneered. The Swiss drugmaker reported a late-stage trial showed a "clinically meaningful benefit" in progression-free survival with a positive trend in overall survival in patients with metastatic prostate cancer that still responds to standard hormone therapy. Almost all of those patients ultimately progress to a form of cancer that no longer responds to hormone therapy, a setting where Pluvicto is already approved, the company added. "These data suggest using (Pluvicto) in an earlier disease setting," Novartis said, adding that this could address a significant unmet need. Novartis only provided a brief summary of trial results and said details would be presented at a medical conference and that it would likely request regulatory approval for wider use in the second half of the year. Pluvicto is part of a class of drugs that combines cell-killing radioactive particles with molecules that attach themselves to tumours, where Novartis has a leading position. The drug saw first-quarter revenue gain 20% to $371 million. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
